Sláma J, Cibula D, Freitag P, Fischerová D, Janousek M, Pavlista D, Strunová M, Zikán M, Jancárková N
Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha.
Ceska Gynekol. 2007 Apr;72(2):116-9.
To compare per-operative and post-operative morbidity in patients undergoing radical surgery for carcinoma of the uterine cervix after administration of a neoadjuvant chemotherapy, and for primarily small cervical tumour.
A retrospective case-control study.
Department of Obstetrics and Gyneacology, 1st Faculty of Medicine, Charles University and General Teaching Hospital, Prague.
The study included 24 patients with squamous cell carcinoma of the uterine cervix who underwent radical hysterectomy including systematic pelvic lymphadenectomy after previous administration of neoadjuvant chemotherapy (NACT) during the period between 1/2004 and 6/2006. The control group of 24 patients was selected retrospectively from the population of women after radical surgery carried out in the same period, nevertheless, the controls underwent the surgery for primarily small carcinoma of the uterine cervix, stages IA2 or IB1. The tumour size consistent with the reduced tumour after NACT administration was the criterion for selection of the control group. The following parameters were monitored in both groups--duration of the surgery, blood loss objectivised by a difference in pre-operative and post-operative haemoglobin and haematocrit values, the need of blood transfusion, per-operative complications, early post-operative complications (up to 6 weeks after the surgery), duration of hospitalization and retaining the inserted epicystotostomy due to hypotonic bladder after discharge.
A therapeutic response allowing the radical surgery was achieved in 92% patients after NACT. After NACT the original tumour volume was reduced by 70% on the average (58% - 100%). No significant differences between the group of patients treated with NACT and undergoing subsequent radical hysterectomy and the control group were reported in terms of duration of the surgery (165 min. vs. 160 min.), blood loss (the difference in pre-operative and post-operative haemoglobin values 18 g/l vs. 19 g/l, the difference in pre-operative and post-operative haematocrit values 0.056 vs. 0.064), administration of blood transfusion (25% vs. 21%) and duration of hospitalization (9.5 days vs. 9.6 days). A significant difference was reported only in the need to retain the inserted epi-cystostomy after discharge (67% vs. 47%).
There were no significant differences in the evaluated parameters of per-operative and postoperative morbidity in patients after NACT and in control patients, except for the necessary duration of artificial urine derivation in patients after NACT due to the fact that their surgery was more radical in the parametria. Administration of NACT regimen involving ifosfamide/cisplatin (IP) improved surgical conditions in the bulky squamous cell carcinoma of the uterine cervix.
比较接受新辅助化疗后行子宫颈癌根治术患者与原发性小宫颈癌患者的术中及术后发病率。
回顾性病例对照研究。
布拉格查理大学第一医学院妇产科及综合教学医院。
本研究纳入了24例子宫颈鳞状细胞癌患者,这些患者在2004年1月至2006年6月期间接受新辅助化疗(NACT)后行根治性子宫切除术及系统性盆腔淋巴结清扫术。对照组24例患者是从同期接受根治性手术的女性人群中回顾性选取的,然而,对照组患者主要接受IA2期或IB1期原发性小子宫颈癌手术。以NACT治疗后肿瘤缩小至与对照组肿瘤大小一致为标准选择对照组。两组均监测以下参数——手术时间、通过术前和术后血红蛋白及血细胞比容值差异客观化的失血量、输血需求、术中并发症、术后早期并发症(术后6周内)、住院时间以及出院后因膀胱低张而保留插入的膀胱造瘘管的情况。
NACT后92%的患者获得了允许进行根治性手术的治疗反应。NACT后原发肿瘤体积平均缩小70%(58% - 100%)。在手术时间(165分钟对160分钟)、失血量(术前和术后血红蛋白值差异18克/升对19克/升,术前和术后血细胞比容值差异0.056对0.064)、输血情况(25%对21%)和住院时间(9.5天对9.6天)方面,接受NACT并随后行根治性子宫切除术的患者组与对照组之间未报告有显著差异。仅在出院后保留插入的膀胱造瘘管的需求方面报告有显著差异(67%对47%)。
NACT后患者与对照患者在术中及术后发病率的评估参数方面无显著差异,除了NACT后患者因手术在宫旁组织更彻底而需要更长时间的人工导尿。采用异环磷酰胺/顺铂(IP)的NACT方案改善了子宫颈大块鳞状细胞癌的手术条件。